Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Operating profit increased due to expanded sales in the Chemicals and Building Materials businesses, higher selling prices and lower production costs in the Chemicals business, and other factors. Meanwhile, profit declined in the Building Materials business due to higher labor and logistics costs, and net income decreased due in part to the recognition of an impairment loss.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥28,032 million (YoY +10.2%) |
| Operating profit | ¥3,404 million (YoY +19.0%) |
| Ordinary income | ¥3,818 million (YoY +18.8%) |
| Profit attributable to owners of the parent | ¥2,281 million (YoY -3.2%) |
| Net income per share | ¥117.25 |
| Operating Margin | 12.1 |
| Equity ratio | End of the current fiscal period 82.4 / End of previous period 85.6 |
| Total assets | ¥61,693 million |
| Net assets | ¥50,824 million |
| Cash flows from operating activities | ¥3,393 million |
| Cash flows from investing activities | ¥4,122 million |
| Cash flows from financing activities | ¥-2,032 million |
| Cash and cash equivalents at end of period | ¥15,779 million |
| Full-year earnings forecast | Net Sales ¥28,640 million (YoY +2.2%) / Operating profit ¥1,310 million (YoY -61.5%) / Ordinary income ¥1,800 million (YoY -52.9%) / Net income ¥1,250 million (YoY -45.2%) |
| Annual Dividend Forecast | 75 yen and sen → 90 yen and sen（+20.0%） |
| Payout ratio | 76.8 |
| Segment revenue | Pharmaceuticals business ¥24,136,990 thousand (YoY +11.1%), Building Materials Business ¥3,895,773 thousand (YoY +4.6%) |
| Segment profit | Pharmaceuticals business ¥3,867,991 thousand (YoY +22.0%), Building Materials Business ¥575,594 thousand (YoY -4.1%) |
| Regional sales | Region Japan / Current fiscal year ¥22,830,903 thousand / Previous period ¥20,680,196 thousand, Region Asia and Oceania / Current fiscal year ¥5,178,274 thousand / Previous period ¥4,760,023 thousand, Region Other / Current fiscal year ¥23,587 thousand / Previous period ¥1,203 thousand |
| Depreciation and amortization | ¥1,104,448 thousand |
| Impairment loss | ¥453,405 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥97 thousand, Gain on sale of investment securities ¥12,348 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥41,480 thousand, Loss on sale of fixed assets ¥188 thousand, Impairment Losses ¥453,405 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 20,280,000 |
| Treasury Shares at Period-End | 819,213 |
| Factors Behind Changes in Business Performance | Operating profit increased due to expanded sales in the Chemicals and Building Materials businesses, higher selling prices and lower production costs in the Chemicals business, and other factors. Meanwhile, profit declined in the Building Materials business due to higher labor and logistics costs, and net income decreased due in part to the recognition of an impairment loss. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Operating profit increased due to expanded sales in the Chemicals and Building Materials businesses, higher selling prices and lower production costs in the Chemicals business, and other factors. Meanwhile, net income attributable to owners of the parent decreased due in part to the recognition of an impairment loss related to the contract manufacturing of lithium-ion battery cathode materials. For the next fiscal year, the company expects the contract manufacturing of lithium-ion battery cathode materials to end in mid-August 2026, as well as the impact of front-loaded fixed costs, capital expenditures, research and development investment, and a challenging external environment.